Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | F11 | P03951 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | HTRA1 | Q92743 | 11/20 | 0.59 |
| ▸ | ELANE | P08246 | 2/20 | 0.59 |
| ▸ | KLK7 | P49862 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tasipeptin A SCHEMBL1593407 | 0.94 | F2 (0.63) | PLGF11F2HTRA1ELANE | |
| Cyanopeptolin 963A SCHEMBL29884137 | 0.85 | PLG (0.78) | PLGF11F2HTRA1ELANE | |
| SCHEMBL24179033 | 0.85 | HTRA1 (0.67) | PLGF11HTRA1ELANEKLK7 | |
| SCHEMBL29884709 | 0.84 | PLG (0.75) | PLGF11F2HTRA1ELANE | |
| SCHEMBL29885836 | 0.84 | F2 (0.66) | PLGF11F2HTRA1ELANE | |
| SCHEMBL6730028 | 0.83 | PLG (0.73) | PLGF11F2HTRA1ELANE | |
| SCHEMBL29886312 | 0.82 | PLG (0.86) | PLGF11F2HTRA1ELANE | |
| Micropeptin E SCHEMBL29884968 | 0.82 | PLG (0.80) | PLGF11F2HTRA1ELANE | |
| Nostopeptin Bn920 SCHEMBL13518016 | 0.82 | KLK7 (0.74) | PLGF11F2HTRA1ELANE | |
| Micropeptin F SCHEMBL29885199 | 0.82 | PLG (0.80) | PLGF11F2HTRA1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183270-B1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | NOVARTIS AG (CH) | 2014-12-17 | — | — | EP | claimed |
| EP-2183270-B1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | NOVARTIS AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-20130172267-A1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8415305-B2 | Use of cyclic depsipeptides to inhibit kallikrein 7 | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20110092437-A1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172267-A1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | KLK7, KLKB1, KLK1 | PLG 42/4885F11 158/4885F2 206/4885 |
| US-20110092437-A1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | KLK7, KLKB1, KLK1 | PLG 42/4885F11 158/4885F2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.